

# ONmentors



## Malcolm Bates

Malcolm is a partner in the Intellectual Property department and Head of Life Sciences in the UK. He works primarily in the life sciences and technology industry sectors.

Malcolm was previously Vice President and General Counsel at Genset in Paris, a NASDAQ-listed biotechnology and bioinformatics company. He speaks regularly on commercial and intellectual property issues. Malcolm has a degree in molecular biology and biochemistry from the University of Durham and a Ph.D. in molecular biology from Imperial College, London. He is the Company Secretary of One Nucleus, the UK's largest biotech network

**T:** 01223 446422  
[www.taylorwessing.com](http://www.taylorwessing.com)  
[m.bates@taylorwessing.com](mailto:m.bates@taylorwessing.com)



## Mary Clarke

Mary has a 20-year successful track record in providing strategic corporate and financial communications to both early- and late-stage healthcare companies.

She has run several high profile PR campaigns and has been instrumental in assisting companies with strategic positioning and fundraising rounds from seed and private financings through IPOs, reverse mergers, as well as numerous follow-on public financings.

Mary has worked with over 100 healthcare clients across Europe and the US including Teva, Bayer, Fresenius Medical Care, Kite Pharmaceuticals, UDG Healthcare, Evotec and BioNTech.

**T:** 0203 714 1788  
[www.optimumcomms.com](http://www.optimumcomms.com)  
[Mary@optimumcomms.com](mailto:Mary@optimumcomms.com)

Mary has built and led healthcare businesses at several international PR&IR agencies. She started her career at BTG plc where she was involved in the Company's IPO and the start-up of several new tech and biotech companies.



## Elisabeth Goodman

Elisabeth Goodman (MAPM, MCLIP) is the owner and Principal Consultant of RiverRhee Consulting, with a focus on creating "exceptional managers and teams".

Prior to starting RiverRhee, Elisabeth was an Information and Library manager in Pharmaceutical R&D, and held internal training and consultancy roles supporting business leaders and teams in global business change programmes.

Elisabeth has a BSc in Biochemistry and an MSc in Information Science. She is accredited in Change Management, Lean Sigma, Belbin Team Roles, MBTI Steps I and II and is an NLP (NeuroLinguistic Programming) Practitioner.

**T:** 07876 130 817  
[www.riverrhee.com](http://www.riverrhee.com)  
[elisabeth@riverrhee.com](mailto:elisabeth@riverrhee.com)



## Jon Green, MPhil CBiol FRSB FRSA FIoD MSyI MBARQA

Jon has held posts in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then as a Senior Scientific Officer with the Medical Research Council. Jon joined Cambridge Antibody Technology (CAT), in 1992 as a Senior Scientist, initially working on several drug discovery projects before moving across to operational management. Jon now holds the post of VP Site General Manager at what is now MedImmune, a wholly-owned subsidiary of AstraZeneca formed through the merger of CAT and MedImmune Inc.

Jon is responsible for leading the site operations of the Cambridge R & D facilities, with specific focus on property, engineering, laboratory and office facilities, security, EHS, procurement, risk management and various scientific services groups. Jon sits on the site leadership team and the global MedImmune Biotech Operations Leadership team.

Jon is also currently Chairman of the Board of One Nucleus, the largest Life Sciences membership organisation in Europe and sits on the Steering committee of the Pharmaceutical Industry Security Forum as Vice Chair. Jon has a masters degree in molecular biology, is a Chartered Biologist, a Fellow of the Royal Society of Biology, Fellow of the Royal Society of Arts and Manufacturing, Fellow of Institute of Directors and a member of the British Association of Research Quality Assurance and Member of the Security Institute.

**T:** 0203 749 6070  
[www.medimmune.com](http://www.medimmune.com)  
[greenj@medimmune.com](mailto:greenj@medimmune.com)

## Stuart Hendry



Stuart is currently CEO of Rinicare, an intelligent healthcare company specialising in AI, wireless sensing and computer vision. He is a medtech/life-science specialist with significant senior management experience in start-ups, SMEs and large corporations. Ex CEO and founder of Sphere Medical plc, and held senior positions at Sagentia plc, Powderject plc and Entrepreneur in Residence at Cambridge University Seed Funds. Track record of successful private and public fundraisings in excess of £50 million in the last 10 years.

**M:** 07780607159  
[stuarthendry\\_taurus@yahoo.com](mailto:stuarthendry_taurus@yahoo.com)

## Derek Jones



Derek is currently CEO at Babraham Bioscience Technologies. He has over 25 years' in the life-science industry as both a scientist and in business development and corporate development, with first-hand experience of establishing biomedical ventures. He has a 1st degree in Chemistry, a MSc in Information Technology, an MBA from Cambridge University Judge Business School and is a Chartered Director. He is a non-executive director at RoCRE at Rothamsted Research, and at One Nucleus. He also sits on the Cambridge University Enterprise Investment Committee.

**T:** +44 01223 496262

## Christian Jones, FRSC

Christian is a seasoned commercial professional in the Pharma and Biotech space and has a strong track record in technology commercialisation, sales and marketing and strategy development and implementation. He is able to quickly understand how best to leverage an organisation's strength to maximise success.

His experience spans the pharma value chain from Drug Discovery to Commercial Manufacturing in a range of organisations from a small Biotech start-up to large CDMO companies. He also has expertise in Respiratory Drug Delivery and Particle Engineering.

He is a chemist by training, a Fellow of the RSC and is passionate about commercialising new technologies.



**T:** 07483007695



## Miranda Knaggs

Miranda is responsible for supporting the development of the Stevenage Bioscience Campus master planning for short, medium and long-term scenarios to achieve Campus vision and strategic objectives. She also leads on all tenancy matters relating to entry criteria, contracts, leases, general tenancy, reviews and audits, business support programmes and corporate and investor relationships.

With 17 years' experience in the biotech sector, she is also Chair of the UK Bio Incubator Forum, representing 24 Bio-Incubators across the UK.

T: 01438 906 906  
[www.stevenagecatalyst.com](http://www.stevenagecatalyst.com)  
Miranda.knaggs@  
stevenagecatalyst.com



## Anne Lane

Anne has a PhD in medicine from UCL and an Executive MBA from Molson Business School, Montreal. After research at UCL and Harvard Medical School, Anne worked for RTP Pharma Inc in Montreal, out-licensing and preparing valuations of the company's portfolio for public listing.

Anne joined UCL Ventures in 2000 and acted as consultant for the National Technology Transfer Centre in the US. She is now Executive Director of UCLB, acts as Director and interim CEO on several of UCLB's spinout companies and oversees the company's licensing activity. Anne is also a member of the Licensing Executives Society (LES) and is on the committee for the Intellectual Property Lawyers Organisation (TIPLo).

T: 020 7679 9000  
[www.uclb.com](http://www.uclb.com)  
a.lane@uclb.com



## Andrew Muncey

Andrew brings over 30 years' experience in finance and management to Artios Pharma. He previously served as Co-founder and Chief Financial Officer of Acacia Pharma, and Chief Executive Officer of Amura Therapeutics. Andrew has been Chief Financial Officer of several healthcare companies, including Bicycle Therapeutics, Kymab, Mission Therapeutics and Virttu Biologics.

Andrew has raised significant amounts of equity and debt funding, including over \$250 million in private equity, and has completed many acquisitions, disposals and restructuring deals in the healthcare market. He has over 15 years' corporate finance and capital markets experience from PricewaterhouseCoopers and UBS.

T: 07989 420 696  
amuncey@outlook.com



## Michael Murray

Dr Michael Murray specialises in commercialising intellectual assets. He has closed 50 transactions applying a rare mix of scientific, technical, IP and deal-making expertise.

His experience includes: board level roles (IP Asset Ventures; Sosei R&D Limited; Amura Therapeutics Limited); consulting/BD&L roles (Wood Mackenzie; BTG International plc; Axis Genetics plc); and at the precursor of the MRC's LifeArc.

Other roles include: Member of the International Technology Transfer Network (China); Advisory Board of the International Chamber of Innovation, Commerce & Enterprise (Japan); Mentor at Cambridge Enterprise and One Nucleus (UK); Course Director (China) for PraxisAuril; and Research Strategy Board of Coeliac UK.

T: +44 (0)7557 805935  
michael.murray@murrayinter-  
nationalpartners.com



## Alan Palmer

Professor Alan Palmer is a neuroscientist and entrepreneur whose career has focussed on brain disorders and their treatment. He has been involved in the formation of several neuroscience-based companies and, in 2005, was voted London Biotechnology Network Entrepreneur of the Year. He holds academic positions at three UK universities (Bristol, Reading and UCL) and is a Board member of four National not-for-profit organisations: One Nucleus, The Brain Tumour Charity, the British Neuroscience Association and the Ellipses Cancer Trust. He is also one of the internationally recognised scientists that sit on the Welsh Government's Sêr Cymru II Evaluation Panel assessing grant applications, a fellow of the Royal Society of Biology and an Honorary member of the Society for Medicines Research.

**T:** 07757 058054  
[prof.palmer@icloud.com](mailto:prof.palmer@icloud.com)



## Tony Sedgwick PhD FRCPATH

Tony is an experienced Entrepreneurial executive He has held various Senior leadership positions in Research and Development becoming World wide head of Clinical operations for Roche .His product successes have been many including Invirase and Tamiflu which have had significant impact both medically and commercially.

Tony has been chief executive officer of four biotechnology companies with two of them successfully exited. He has also been chairman of a number of European and British Biotechnology companies .

During the last few years tony has specialised in "trusted" advisory roles for CEOs and R and D heads. He has a deep belief that people are the key to the fast moving technology space .The human not the machine part will be unique selling point for business in the future where innovation and creativity is key. His blog site is suitably named [www.thoughtdisruptor.com](http://www.thoughtdisruptor.com)

**T:** +447785290408  
[www.thoughtdisruptor.com](http://www.thoughtdisruptor.com)  
[TonySedgwick@mac.com](mailto:TonySedgwick@mac.com)



## Linda Summerton MA, PhD

Linda is a Senior Partner with TranScript bringing a wealth of experience in leading clinical and cross functional development teams to create strategic development options, associated development plans, and to deliver to quality, time and cost. Asset identification, due diligence and asset management for investment funds in the pharma and medtech space are also part of her skill set.

With over 25 years in the global pharmaceutical industry in large Pharmaceutical companies, small biotechnology companies and private equity ventures, Linda's main areas of therapeutic expertise are oncology and respiratory, although she has significant experience in cardiovascular, infection, inflammation and CNS.

**M:** +44 (0)773 066 7539  
**T:** +44 (0)118 963 7846  
[www.transcrip-partners.com](http://www.transcrip-partners.com)



## Craig Titmus

Craig is a patent attorney and partner at Mathys & Squire LLP. His practice covers diverse biotechnological subject-matter, with a particular focus on vaccines, diagnostics, therapeutic antibodies and peptide conjugates, biofuels and clean technologies. Craig has significant experience of European and international patent prosecution, and coordinates global IP strategies for a range of clients including start-ups, SMEs, universities, large corporations and the UK Government.

Craig holds an undergraduate degree in molecular biology and biochemistry from the University of Durham, and a PhD in biotechnology from the University of Cambridge.

**T:** +44 (0) 207 830 0000  
[CETitmus@mathys-squire.com](mailto:CETitmus@mathys-squire.com)  
[www.mathys-squire.com/](http://www.mathys-squire.com/)